

## Appendix F: CIBMTR Publications

---

### 2008 CIBMTR Publications

Lee SJ, Kamani N, Confer DL. Principles and tools for selection of umbilical cord blood and unrelated adult donor grafts. *Biol Blood Marrow Transplant* 14:112-119, 2008

Kamani N, Spellman S, Hurley CK, Barker JN, Smith FO, Oudshoorn M, Bray R, Smith A, Williams TM, Logan B, Eapen M, Anasetti C, Setterholm M, Confer DL. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. *Biol Blood Marrow Transplant* 14:1-6, 2008

Schlenk RF, Pasquini MC, Pérez WS, Zhang M-J, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn J-Y, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, İlhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Arnold Ganser A. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. *Biol Blood Marrow Transplant* 14:187-196, 2008

Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo M, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. *Biol Blood Marrow Transplant* 14:236-245, 2008

Eapen M, Zhang MJ, Devidas M, Raetz E, Barredo JC, Ritchey AK, Godder K, Grupp S, Lewis VA, Malloy K, Carroll WL, Davies SM, Camitta BM. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Leukemia* 22:281-286, 2008

Hou L, Steiner NK, Chen M, Belle I, Kubit AL, Ng J, Hurley CK. Limited allelic diversity of stimulatory two-domain killer cell immunoglobulin-like receptors. *Hum Immunol* 69:174–178, 2008

Scheike TH, Zhang MJ, Gerdts TA. Predicting cumulative incidence probability by direct binomial regression. *Biometrika* 95:205-220, 2008

Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the US: implications for umbilical cord blood storage. *Biol Blood Marrow Transplant* 14:316-322, 2008

Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, MD, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. *Bone Marrow Transplant* 41:537-545, 2008

Klein JP, Gerster M, Andersen PK, Tarima S, Perme MP. SAS and R functions to compute pseudo-values for censored data regression. *Comput Methods Programs Biomed* 89:289-300, 2008

Howard DH, Meltzer D, Kollman C, Maiers M, Logan B, Gragert L, Setterholm M, Horowitz MM. Use of cost-effectiveness analysis to determine inventory size for a national cord blood bank. *Med Decis Making* 28:243-253., 2008

Williams TM, Winden T, Setterholm M, Vierra-Green CA, Spellman S, Flesch S, Awdeh Z, Baxter-Lowe LA, Begovich AB, Fernandez-Vina M, Hegland J, Hurley CK, Johnson D, Noreen H, Salazar M, Schmeckpeper B, Yunis EJ. Strategies and technical challenges in allele level Class II typing in 2578 bone marrow transplantation donor-recipient pairs. *Hum Immunol* 69:227-234, 2008

Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn J-Y, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller C, Sierra J, Milone G, Keating A, Loberiza, FR, Jr, Giralt SA, Horowitz MM, Weisdorf DJ. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. *Bone Marrow Transplant* 41:635-642, 2008

Perez-Albuerne ED, Eapen M, Klein JP, Gross TG, Lipton JM, Baker KS, Woolfrey AE, Kamani NR. Outcome of unrelated donor stem cell transplantation for children with severe Aplastic anemia. *Br J Haematol* 141:216-223., 2008

Belle I, Hou L, Chen M, Steiner NK, Ng J, Hurley CK. Investigation of killer cell immunoglobulin-like receptor gene diversity in KIR3DL1 and KIR3DS1 in a transplant population. *Tissue Antigens* 71:434-439, 2008

Gardner SL, Carreras J, Boudreau C, Camitta BM, Adams RH, Chen AR, Davies SM, Edwards JR, Groves AC, Hale GA, Lazarus HM, Arora M, Stiff PJ, Eapen M. Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. *Bone Marrow Transplant* 41:867-872, 2008

Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M, Kernan NA, Loberiza Jr. FR, Soiffer RJ, Eapen M. Individual physician practice variation in hematopoietic cell transplantation. *J Clin Oncol* 26:2162-2170, 2008

Mulrooney TJ, Hou L, Steiner NK, Chen M, Belle I, Ng J, Hurley CK. Promoter variants of KIR2DL5 add to diversity and may impact gene expression. *Immunogenetics* 60:287-294, 2008

Weinstock DM, Case Jr. C, Bader JL, Chao NJ, Coleman CN, Hatchett RJ, Weisdorf DJ, Confer DL. Radiological and nuclear events: contingency planning for hematologist/oncologists. *Blood* 111:5440-5445, 2008

Weinstock DM, Case, Jr. C, Confer DL. Response: radiologic and nuclear events. *Blood* 111:5758-5759, 2008

Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. On the probability of using cord blood. *Biol Blood Marrow Transplant* 14:724-725, 2008

Marks DI, Pérez WS, He W, Zhang M-J, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. *Blood* 112:426-434, 2008

Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. *Biol Blood Marrow Transplant* 14:748-758, 2008

- Confer D, Robinett P The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation. *Bone Marrow Transplant* 42:S3-S5, 2008
- Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlosky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus, HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant *Biol Blood Marrow Transplant* 14:904-912, 2008
- Horowitz MM. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. *Bone Marrow Transplant* 42:S1-S2, 2008
- Baker KS, Filipovich AH, Gross TG, Grossman WJ, Hale GA, Hayashi RJ, Kamani NR, Kurian S, Kapoor N Ringdén O, Eapen M. Unrelated donor hematopoietic cell transplantation for hemaophagocytic lymphohistiocytosis. *Bone Marrow Transplant* 42:175-180, 2008
- Levine JE, Barrett AJ, Zhang M-J, Pulsipher MA, Bunin N, Fort J, Loberiza FR, Porter D, Giralt S, Drobyski W, Ringdén O, Horowitz MM, Collins R. Donor leukocyte infusions to treat hematologic malignancy relapse following allogeneic stem cell transplantation in a pediatric population. *Bone Marrow Transplant* 42:201-205, 2008
- Ballen KK, King RJ, Chitphakdithai P, Bolan Jr. CD, Agura E, Hartzman RJ, Kernan NA The National Marrow Donor Program 20 years of unrelated donor hematopoietic cell transplantation. *Blood Marrow Transplant* 14:2-7, 2008
- Bolan CD, Hartzman RJ, Perry EH, Trainor L, Miller J, Miller R, Hanley L, Chitphakdithai P, King RJ Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program. *Biol Blood Marrow Transplant* 14:23-28, 2008
- Bray RA, Hurley CK, Kamani NR, Woolfrey A, Müller C, Spellman S, Setterholm M, Confer DL. National Marrow Donor Program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. *Biol Blood Marrow Transplant* 14:45-53, 2008
- MacMillan ML, Davies SM, Nelson GO, Chitphakdithai P, Confer DL, King RJ, Kernan NA Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. *Biol Blood Marrow Transplant* 14:16-22, 2008
- Miller JP, Perry EH, Price TH, Bolan Jr. CD, Karanes C, Boyd TM, Chitphakdithai P, King RJ. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. *Biol Blood Marrow Transplant* 14:29-36, 2008
- Spellman S, Setterholm M, Maiers M, Noreen H, Oudshoorn M, Fernandez-Viña M, Petersdorf E, Bray R, Hartzman RJ, Ng J, Hurley CK. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. *Biol Blood Marrow Transplant* 14:37-44, 2008
- Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA, Horowitz MM, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA. Outcomes following HCT using Fludarabine, Busulfan and Thymoglobulin: A matched comparison to allogeneic transplants conditioned with Busulfan and Cyclophosphamide. *Biol Blood Marrow Transplant* 14:993-1003, 2008
- Duquesnoy R, Spellman S, Haagenson M, Wang T, Horowitz MM, Oudshoorn M. HLA matchmaker-defined triplet matching is not associated with better survival rates of patients with

class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant 14:1064-1071, 2008

Logan BR, Klein JP, Zhang MJ. Comparing treatments in the presence of crossing survival curves: An application to bone marrow transplantation. Biometrics 64:733-740, 2008

Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol 26:4326-4332, 2008

Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DL. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 14:8-15, 2008

Bashey A, Pérez WS, Zhang M-J, Anderson KC, Ballen K, Berenson JR, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant 14:1118-1124, 2008

Kumar S, Pérez WS, Zhang M-J, Ballen K, Bashey A, Bik To L, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JA, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in non-secretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 14:1134-1140, 2008

Pasquini R, Carreras, J, Pasquini MC, Camitta BM, Fasth AL, Hale GA, Harris RE, Marsh JC, Robinson AJ, Zhang M-J, Eapen M, Wagner JE. HLA-matched sibling hematopoietic stem cell transplantation for Fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant 14:1141-1147, 2008

Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khouri HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112:3500-3507, 2008

Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R, Jagasia M, Kernan NA, Loberiza FR, Jr, Bevans M, Soiffer RJ, Joffe S. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 14:1231-1238, 2008

Murphey E. Helping survivors thrive after marrow and cord blood transplants. Coping 2008; Nov/Dec:18, 2008

Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz MM, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 112:4425-4431, 2008

Eapen M, Rocha, V. Principles and analysis of hematopoietic cell transplantation: the physician's eye-view. Lifetime Data Anal 14:379-388, 2008

Logan BR, Nelson GO, Klein JP. Analyzing center specific outcomes in hematopoietic cell transplantation. Lifetime Data Anal. 14:389-404, 2008

Liu L, Logan B, Klein JP. Inference for current leukemia free survival. Lifetime Data Anal 14:432-446, 2008

Scheike TH and Zhang M-J. Flexible competing risks regression modelling and goodness-of-fit. Lifetime Data Anal 14:464-483, 2008

Lazarus HM, Carreras J, Boudreau C, Loberiza FR, Jr, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Rizzo JD. Influence of age and histology on outcome in adult non-hodgkin's lymphoma patients undergoing autologous HCT: a report from the Center for International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 14:1323-1333, 2008

Dehn J, Arora M, Spellman S, Setterholm M, Horowitz M, Confer D, Weisdorf D. Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match. Biol Blood Marrow Transplant 14:1334-1340, 2008

Logan B, Leifer E, Bredeson C, Horowitz M, Ewell M, Carter S, Geller N. Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clin Trials 5:607-616, 2008

Majhail NS. Mobilization and Transplantation, Old and new cancers after hematopoietic-cell transplantation. Hematology 2008, American Society of Hematology, Education Program Book, San Francisco, CA, December 6-9, (Gewirtz AM, Muchmore EA, Burns LJ, eds.), American Society of Hematology, Washington, D.C., pp 142-149., 2008

Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia J Clin Oncol 26:5728-5734, 2008

Klein JP, Zhang MJ Guest editor introduction to issue on transplant statistics Lifetime Data Analysis, 14:377-378, 2008

Bajorunaite, R and Klein, JP Comparing failure probabilities in the presence of competing risks J of Statistical Computation and Simulation 78:951-66, 2008

Klein, JP and da Silva Direct Regression models for survival parameters basedf on pseudovalues Frontiers of Applied and Computational Mathematics (Blackmore, D., Boses, A and Petropoulos P, eds) World Scientific, Hackensack, NJ 162-171, 2008

Zhang MJ, Zhang X, Scheike TH. Modeling Cumulative Incidence Function for Competing Risks Data. Expert Review of Clinical Pharmacology, 1:391-400, 2008

Zhang MJ, Fine J. Summarizing Differences in Cumulative Incidence Functions. Statistics in Medicine 27:4939-4949, 2008

## 2009 CIBMTR Publications

Devetten MP, Hari P, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz, Vose JM, Lazarus HM, Anderlini P. Unrelated donor reduced-intensity and nonmyeloablative stem cell transplantation for patients with relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 15:109-117, 2009

Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le C, Marsh SGE, Guethlein LA, Parham P, Miller JS, Weisdorf DJ. Donors with group B KIR haplotypes improve relapse-

free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. *Blood* 113:726-732, 2009

Aljurf MD, Zaidi SZ, El Solh H, Hussain F, Ghavamzadeh A, Mahmoud HK, Shamsi T, Ben Othman T, Sarhan MM, Dennison D, Ibrahim A, Benchekroun S, Chaudhri N, Labar B, Horowitz M, Niederwieser D, Gratwohl A. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. *Bone Marrow Transplant* 43:1-12, 2009

Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers MED, Friedman D, Horowitz MM, Wingard JR, Deeg HJ. Solid cancers after allogeneic hematopoietic cell transplantation. *Blood* 113:1175-1183, 2009

Tunes da Silva G, Logan BR, Klein JP. Methods for equivalence and noninferiority testing. *Biol Blood Marrow Transplant* 15:120-127, 2009

Holdsworth R, Hurley C, Marsh SGE, Lau M, Noreen H, Kempenich J, Setterholm M, Maiers M. The HLA Dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. *Tissue Antigens* 73:95-170, 2009

Qasim W, Cavazzana-Calvo M, Davies EG, Davis J, Duval M, Eames G, Farinha N, Filopovich A, Fischer A, Friedrich W, Genery A, Heilmann C, Landais P, Horwitz ME, Porta F, Sedlacek P, Seger R, Slatter M, Teague L, Eapen M, Veys P. Allogeneic stem cell transplantation for leukocyte adhesion deficiency. *Pediatrics* 123:836-840, 2009

Thornley I, Eapen M, Sung L, Lee SJ, Davies SM, Joffe S. Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physicians. *Pediatrics* 123:1011-1017, 2009

Ringdén O, Pavletic S, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. *Blood* 113:3110-3118, 2009

Gale RP, Eapen M, Logan B, Zhang MJ, Lazarus HM. Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants? *Bone Marrow Transplant* 43:435-446, 2009

Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, MacMillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants *Biol Blood Marrow Transplant* 15:360-366, 2009

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant* 15:367-369, 2009

Tunes da Silva G, Klein JP. Regression Analysis of Mean Quality-Adjusted Survival Time Based on Pseudo-Observations. *Statistics in Medicine* 28:1054-1066, 2009

Lazaro, AM, Xiao Y, Regenscheid A, Ng J, Hurley CK, Posch PE. Characterization of 104 novel alleles at the HLA-A, -B, and DRB1 loci from National Marrow Donor Program volunteer donors. *Tissue Antigens* 73:364-372, 2009

Arora M, Weisdorf DJ, Spellman S, Haagenson M, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C, Nademanee A, McGlave P, Horowitz MM, Petersdorf E. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. *J Clin Oncol.* 27:1637-1643, 2009

Pulsipher MA, Chitphakdithai P, Miller J, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson M, Kurian S, Klein JP, Horowitz MM, Confer DL. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. *Blood* 113:3604-3611, 2009

Xiao Y, Lazaro AM, Masaberg C, Haagenson M, Vierra-Green C, Spellman S, Dakshanamurthy S, Ng J, Hurley CK. Evaluating the potential impact of mismatches outside of the antigen recognition site in unrelated hematopoietic stem cell transplantation: HLA-DRB1\*1454 and DRB1\*140101. *Tissue Antigens* 73:595-598, 2009

van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. *Biol Blood Marrow Transplant* 15:554-563, 2009

Lazarus HM, Kan F, Tarima S, Champlin RE, Confer D, Frey N, Gee AP, Wagner JE, Horowitz MM, Eapen M. Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. *Biol Blood Marrow Transplant* 15:589-596, 2009

Horan J, Carreras J, Tarima S, Camitta BM, Gale RP, Hale GA, Hinterberger W, Marsh J, Passweg JR, Walters MC, Mary Eapen M. Risk factors affecting outcome of second HLA-matched sibling donor transplantation for graft failure in severe acquired Aplastic anemia. *Biol Blood Marrow Transplant* 15:626-631, 2009

Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. *Blood* 113:4992-5001, 2009

Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhäuser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. *Br J Haematol* 145:816-24, 2009

Spellman SR, Warden MB, Haagenson MD, Pietz BC, Goulmy E, Warren EH, Wang T, Ellis TM. Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. *Biol Blood Marrow Transplant* 15:856-863, 2009

Gupta V, Tomblyn M, Pedersen TL, Atkins HL, MD, Battiwalla M, Gress RE, Pollack M, Storek J, Thompson JC, Tiberghien P, Young J-A, Ribaud P, Horowitz M, Keating A. Allogeneic hematopoietic cell transplantation in HIV-positive patients with hematological disorders: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). *Biol Blood Marrow Transplant* 15:864-871, 2009

Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, DiFronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. *Blood* 114:511-517, 2009

- Shah R, Selby ST, Yokley B, Slack RS, Hurley CK, Posch PE TNF, LTA and TGFB1 genotype distributions among acute graft versus host disease (aGVHD) subsets after HLA-matched unrelated hematopoietic stem cell transplantation: a pilot study. *Tissue Antigens* 74:50-56, 2009
- Loberiza FR, Jr., Lee SJ, Freytes CO, Giralt SA, Van Besien K, Kurian S, Del Ciero P, Toro JJ, Williams LA, Ketelsen SW, Navarro WH, Rizzo JD. Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 15:903-909, 2009
- Baxter-Lowe LA, Maiers M, Spellman SR, Haagenson MD, Wang T, Fernandez-Vina M, Marsh SG, Horowitz M, Hurley CK HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States. *Biol Blood Marrow Transplant* 15:971-81, 2009
- Hari P, Zhang M-J, Roy V, Pérez WS, Bashey A, Bik To L, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D. Is the International staging system superior to the Durie Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. *Leukemia* 23:1528-1534, 2009
- Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, Horowitz MM, Miller JP, King RJ, Confer DL Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+cell dose. *Blood* 114:2606-2616, 2009
- Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A, Burns LJ, Gupta V, Ho V, McCarthy PL, Ringden O, Schouten HC, Seftel M, Rizzo JD The effect of smoking on allogeneic transplant outcomes. *Biol Blood Marrow Transplant* 15:1277-1287, 2009
- Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang M-J, Rizzo JD. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. *Br J Haematol* 147:129–139, 2009
- Pamphilon D, Siddiq S, Brunsell S, Dorée C, Hyde C, Horowitz M, Stanworth S Stem cell donation – What advice can be given to the donor? *Br J Haematol* 147:71-76, 2009
- Confer D, Gress R, Tomblyn M, Ehninger G Hematopoietic cell graft safety Bone Marrow Transplant 44:463–465, 2009
- Fenske TS, Hari PN, Carreras J, Zhang M-J, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen Y-B, Freytes CO, Gale RP, Hale GA, Ilhan O, Khouri HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM Impact of pre-transplant Rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma *Biol Blood Marrow Transplant* 15:1455-1464, 2009
- Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn J-Y, Cervantes F, Copelan E, Gale R, Gratwohl A, Khouri HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, Horowitz MM, Arora M Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse *Biol Blood Marrow Transplant* 15:1475-1478, 2009
- Anderson E, Grzywacz B, Wang H, Wang T, Haagenson M, Spellman S, Blazar BR, Miller JS, Verneris MR Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation *Blood* 114:4753-4754, 2009

Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. Impending challenges in the hematopoietic stem cell transplant physician workforce. *Biol Blood Marrow Transplant* 15:1493-1501, 2009

Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen, KK Bigelow CL, Haydar A, Frangoul HA, Hard CL, Lee SJ, Rizzo JD. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 15:1543-1554, 2009

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M. Defining the intensity of conditioning regimens: working definitions. *Biol Blood Marrow Transplant* 15:1628-1633, 2009

Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. *J Allergy Clin Immunol* 124:1152-1160, 2009

Horowitz MM. High-resolution typing for unrelated donor transplantation: how far do we go? *Best Pract Res Clin Haematol* 22:537-541, 2009

Friedner TM, Chao NJ, Bader JL, Boettger A, Case C Jr, Chute J, Confer DL, Ganser A, Gorin NC, Gourmelon P, Graessle DH, Krawisz R, Meineke V, Niederwieser D, Port M, Powles R, Sirohi B, Weinstock DM, Wiley A, Coleman CN. Stem cells, multiorgan failure in radiation emergency medical preparedness: a U.S./European Consultation Workshop. *Stem Cells* 27:1205-1211, 2009

Zhang X, Zhang MJ, Fine JP. A Mass Redistribution Algorithm for Right-censored and Left-truncated Time to Event Data. *J of Stat Planning and Inference* 9:3329-3339, 2009

Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective Co-published in *Biol Blood Marrow Transplant* 15:1143-1238, 2009; *Bone Marrow Transplant* 44:453-455, 2009, 2009